Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement

Stock Track

02/28

ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.

The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.

Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1121764006"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121764006\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121764006?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121764006","market":"nz","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-28 07:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1121764006","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121764006","pubTimestamp":1772235669,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后飙升5.11%，因即将发布业务更新和2025财年财务业绩公告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}